Sign in

You're signed outSign in or to get full access.

Stevie

Vice President and Equity Research Analyst at Jefferies

Stevie Wonder is a Vice President and Equity Research Analyst at Jefferies, specializing in consumer and retail sector research with a focus on apparel, footwear, and luxury goods. He covers specific companies including Nike, Lululemon Athletica, VF Corporation, Tapestry, and Ralph Lauren, boasting a strong performance track record with a 68% success rate on TipRanks, top 10% ranking among retail analysts, and average return of 14.2% per rating. Wonder started his career at Goldman Sachs as a research associate in 2015, advanced to Associate at Barclays in 2018, and joined Jefferies in 2021 to take on his current VP role. He holds Series 7, 63, and 87 FINRA licenses, along with an MBA from NYU Stern School of Business.

Stevie's questions to NEUROCRINE BIOSCIENCES (NBIX) leadership

Question · Q4 2025

Stevie asked about the importance of the initiated Phase II study for CRENESSITY in patients under four years old, when an update is expected, and if this represents a significant growth opportunity upon potential market approval.

Answer

Chief Medical Officer Sanjay Keswani confirmed the initiation of study 2032 for pediatric patients aged three months to under four years, with the intent to expand CRENESSITY's label beyond the current four years and above. He stated that data from this study is expected next year, representing a future growth opportunity.

Ask follow-up questions

Fintool

Fintool can predict NEUROCRINE BIOSCIENCES logo NBIX's earnings beat/miss a week before the call

Question · Q4 2025

Stevie asked about CRENESSITY's pipeline, specifically the initiation of a Phase 2 study for patients under four years old, its importance, expected update timeline, and potential as a growth opportunity.

Answer

Sanjay Keswani, Chief Medical Officer, confirmed the upcoming initiation of study 2032, a pediatric study for individuals less than four years of age (down to three months), with the intent to expand CRENESSITY's label beyond the current four years and above. He stated that data from this study is expected next year.

Ask follow-up questions

Fintool

Fintool can write a report on NEUROCRINE BIOSCIENCES logo NBIX's next earnings in your company's style and formatting